Polymorphic nanobody crystals as long‐acting intravitreal therapy for wet age‐related macular degeneration

Abstract Wet age‐related macular degeneration (wet AMD) is the most common cause of blindness, and chronic intravitreal injection of anti‐vascular endothelial growth factor (VEGF) proteins has been the dominant therapeutic approach. Less intravitreal injection and a prolonged inter‐injection interval are the main drivers behind new wet AMD drug innovations. By rationally engineering the surface residues of a model anti‐VEGF nanobody, we obtained a series of anti‐VEGF nanobodies with identical protein structures and VEGF binding affinities, while drastically different crystallization propensities and crystal lattice structures. Among these nanobody crystals, the P212121 lattice appeared to be denser and released protein slower than the P1 lattice, while nanobody crystals embedding zinc coordination further slowed the protein release rate. The polymorphic protein crystals could be a potentially breakthrough strategy for chronic intravitreal administration of anti‐VEGF proteins.